Home

GERALDINE HENWOOD

CIK 1236451 · President and CEO · last filed 2022-12-19

GERALDINE HENWOOD is a President and CEO who has filed 67 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider bought $3.1K of BXRX on Dec 19, 2022. Across all open-market trades the lifetime net is −$7.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $281.1K across reported positions. 31 SEC filings were submitted jointly with Recro Pharma, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$281.1K

Companies

5

Total Filings

67

Lifetime Open-Market Net

-$7.41M

Filer Profile

Reported Address
88 SIDNEY ST
CAMBRIDGE, MA 02139
Related Filers
Recro Pharma, Inc. — 31 joint filings, latest 2021-05-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Baudax Bio, Inc. (BXRX) Delisted President and CEO 2,441 $0.02 $53 $12.8K 10 2022-12-19
Societal CDMO, Inc. (REPH) Delisted Director 276,574 $2.09 $578.0K -$2.56M 28 2021-05-17
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Director — — — $0 5 2019-06-11
ALKS Director 0 $45.97 $0 -$4.08M 13 2014-01-17
MAPP Director 10,000 $28.11 $281.1K -$777.3K 11 2013-03-04

Recent Filings

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-12-19 Baudax Bio, Inc. (BXRX) Delisted Buy (P) +1,200 $3.1K EDGAR
2022-06-17 Baudax Bio, Inc. (BXRX) Delisted Grant (A) +39,473 $0 EDGAR
2021-12-23 Baudax Bio, Inc. (BXRX) Delisted Mixed −18,636 -$5.8K EDGAR
2021-12-14 Baudax Bio, Inc. (BXRX) Delisted Tax (F) −9,155 -$3.2K EDGAR
2021-09-23 Baudax Bio, Inc. (BXRX) Delisted Buy (P) +8,200 $4.8K EDGAR
2021-05-17 Societal CDMO, Inc. (REPH) Delisted Grant (A) — $0 EDGAR
2021-05-10 Baudax Bio, Inc. (BXRX) Delisted Buy (P) +6,000 $5.0K EDGAR
2021-04-22 Societal CDMO, Inc. (REPH) Delisted Grant (A) +26,923 $0 EDGAR
2021-04-15 Societal CDMO, Inc. (REPH) Delisted Grant (A) — $0 EDGAR
2021-01-22 Baudax Bio, Inc. (BXRX) Delisted Grant (A) +65,435 $0 EDGAR
Showing 1–10 of 67
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.